TCM
CRSP icon

TD Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

TD Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-255
Closed -$39K – 324
2020
Q4 		$39K Buy
+255
New +$30.1K 0.01% 143

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

TD Capital Management's CRSP Position: Q1 2021 in Review

TD Capital Management sold out of CRISPR Therapeutics (CRSP) in Q1 2021, closing a stake of 255 shares — an estimated $39K sold.

TD Capital Management first reported a position in CRSP in Q4 2020 and held it in 1 quarter. The position peaked at $39K in Q4 2020. 443 funds tracked by Wall St. Rank hold CRSP as of Q1 2021.

  • TD Capital Management reported no remaining CRISPR Therapeutics position as of Q1 2021 after selling out during the quarter.
  • TD Capital Management sold 255 CRISPR Therapeutics shares in Q1 2021, an estimated $39K.
  • TD Capital Management first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 1 quarter.
  • TD Capital Management's CRISPR Therapeutics position peaked at $39K in Q4 2020.
  • 443 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2021.

Based on TD Capital Management's 13F filing for Q1 2021, filed 10 May 2021.